New cancer drug targets tumor weakness in early human trial
NCT ID NCT07260513
Summary
This is the first human study of an experimental drug called GH2616 for women with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and understand how the body processes the drug. Researchers will enroll 126 participants with specific advanced gynecological cancers or triple-negative breast cancer to test whether GH2616 can help control tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.